Increased risk of type 2 diabetes in Alzheimer disease.

Alzheimer disease and type 2 diabetes are characterized by increased prevalence with aging, a genetic predisposition, and comparable pathological features in the islet and brain (amyloid derived from amyloid beta protein in the brain in Alzheimer disease and islet amyloid derived from islet amyloid polypeptide in the pancreas in type 2 diabetes). Evidence is growing to link precursors of amyloid deposition in the brain and pancreas with the pathogenesis of Alzheimer disease and type 2 diabetes, respectively. Given these similarities, we questioned whether there may be a common underlying mechanism predisposing to islet and cerebral amyloid. To address this, we first examined the prevalence of type 2 diabetes in a community-based controlled study, the Mayo Clinic Alzheimer Disease Patient Registry (ADPR), which follows patients with Alzheimer disease versus control subjects without Alzheimer disease. In addition to this clinical study, we performed a pathological study of autopsy cases from this same community to determine whether there is an increased prevalence of islet amyloid in patients with Alzheimer disease and increased prevalence of cerebral amyloid in patients with type 2 diabetes. Patients who were enrolled in the ADPR (Alzheimer disease n = 100, non-Alzheimer disease control subjects n = 138) were classified according to fasting glucose concentration (FPG) as nondiabetic (FPG <110 mg/dl), impaired fasting glucose (IFG, FPG 110-125 mg/dl), and type 2 diabetes (FPG >126 mg/dl). The mean slope of FPG over 10 years in each case was also compared between Alzheimer disease and non-Alzheimer disease control subjects. Pancreas and brain were examined from autopsy specimens obtained from 105 humans (first, 28 cases of Alzheimer disease disease vs. 21 non-Alzheimer disease control subjects and, second, 35 subjects with type 2 diabetes vs. 21 non-type 2 diabetes control subjects) for the presence of islet and brain amyloid. Both type 2 diabetes (35% vs. 18%; P < 0.05) and IFG (46% vs. 24%; P < 0.01) were more prevalent in Alzheimer disease versus non-Alzheimer disease control subjects, so 81% of cases of Alzheimer disease had either type 2 diabetes or IFG. The slope of increase of FPG with age over 10 years was also greater in Alzheimer disease than non-Alzheimer disease control subjects (P < 0.01). Islet amyloid was more frequent (P < 0.05) and extensive (P < 0.05) in patients with Alzheimer disease than in non-Alzheimer disease control subjects. However, diffuse and neuritic plaques were not more common in type 2 diabetes than in control subjects. In cases of type 2 diabetes when they were present, the duration of type 2 diabetes correlated with the density of diffuse (P < 0.001) and neuritic plaques (P < 0.01). In this community cohort from southeast Minnesota, type 2 diabetes and IFG are more common in patients with Alzheimer disease than in control subjects, as is the pathological hallmark of type 2 diabetes, islet amyloid. However, there was no increase in brain plaque formation in cases of type 2 diabetes, although when it was present, it correlated in extent with duration of diabetes. These data support the hypothesis that patients with Alzheimer disease are more vulnerable to type 2 diabetes and the possibility of linkage between the processes responsible for loss of brain cells and beta-cells in these diseases.

[1]  B. Winblad,et al.  Changes in blood glucose and insulin secretion in patients with senile dementia of Alzheimer type. , 2009, Acta medica Scandinavica.

[2]  Carl W. Cotman,et al.  Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis , 2003, Science.

[3]  M. Dragunow,et al.  Increased Expression and Activation of c-Jun Contributes to Human Amylin-induced Apoptosis in Pancreatic Islet β-Cells , 2002 .

[4]  P. Lansbury,et al.  Neurodegenerative disease: Amyloid pores from pathogenic mutations , 2002, Nature.

[5]  K. Rockwood,et al.  Diabetes mellitus and the Risk of Dementia, Alzheimer’s Disease and Vascular Cognitive Impairment in the Canadian Study of Health and Aging , 2002, Dementia and Geriatric Cognitive Disorders.

[6]  R. Mayeux,et al.  Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort. , 2001, American journal of epidemiology.

[7]  L. Groop,et al.  Cardiovascular morbidity and mortality associated with the metabolic syndrome. , 2001, Diabetes care.

[8]  Z. Makita,et al.  Immunohistochemical distribution of the receptor for advanced glycation end products in neurons and astrocytes in Alzheimer’s disease , 2001, Brain Research.

[9]  G. Cooper,et al.  Role of Ca2+ in apoptosis evoked by human amylin in pancreatic islet beta-cells. , 1999, The Biochemical journal.

[10]  G. Cooper,et al.  Induction of apoptosis by human amylin in RINm5F islet β‐cells is associated with enhanced expression of p53 and p21WAF1/CIP1 , 1999, FEBS letters.

[11]  D. Harrison,et al.  The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediate-sized toxic amyloid particles. , 1999, Diabetes.

[12]  T. Harris,et al.  Longitudinal association of vascular and Alzheimer’s dementias, diabetes, and glucose tolerance , 1999, Neurology.

[13]  P. Raskin,et al.  Report of the expert committee on the diagnosis and classification of diabetes mellitus. , 1999, Diabetes care.

[14]  Z. Makita,et al.  Advanced glycation end products in Alzheimer's disease and other neurodegenerative diseases. , 1998, The American journal of pathology.

[15]  S. Estus,et al.  Human Amylin Induces “Apoptotic” Pattern of Gene Expression Concomitant with Cortical Neuronal Apoptosis , 1998, Journal of neurochemistry.

[16]  H. Hakola.  Benton’s Visual Retention Test in Patients with Polycystic Lipomembranous Dysplasia with Sclerosing Leukoencephalopathy , 1997, Dementia and Geriatric Cognitive Disorders.

[17]  J. Heitner,et al.  Diabetics do not have increased Alzheimer-type pathology compared with age-matched control subjects , 1997, Neurology.

[18]  A. Ott.  Risk of dementia: The Rotterdam Study , 1997 .

[19]  A. Schmidt,et al.  What's the RAGE? The receptor for advanced glycation end products (RAGE) and the dark side of glucose , 1997, European journal of clinical investigation.

[20]  P. O'Brien,et al.  Risk of dementia among persons with diabetes mellitus: a population-based cohort study. , 1997, American journal of epidemiology.

[21]  C. Finch,et al.  Aging, Metabolism, and Alzheimer Disease: Review and Hypotheses , 1997, Experimental Neurology.

[22]  C. Cotman,et al.  Apolipoprotein‐E Genotyping of Diabetic Dementia Patients: Is Diabetes Rare in Alzheimer's Disease? , 1996, Journal of the American Geriatrics Society.

[23]  W. Soeller,et al.  Treatment With Growth Hormone and Dexamethasone in Mice Transgenic for Human Islet Amyloid Polypeptide Causes Islet Amyloidosis and β-Cell Dysfunction , 1996, Diabetes.

[24]  B. Kagan,et al.  Pore Formation by the Cytotoxic Islet Amyloid Peptide Amylin (*) , 1996, The Journal of Biological Chemistry.

[25]  J. Hanlon,et al.  Do Older Women Use Estrogen Replacement? Data from the Duke Established Populations for Epidemiologic Studies of the Elderly (EPESE) , 1996, Journal of the American Geriatrics Society.

[26]  N. Eberhardt,et al.  Human islet amyloid polypeptide expression in COS-1 cells. A model of intracellular amyloidogenesis. , 1995, The American journal of pathology.

[27]  C. Behl,et al.  Amyloid peptides are toxic via a common oxidative mechanism. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[28]  S. M. Sumi,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part X. Neuropathology Confirmation of the Clinical Diagnosis of Alzheimer's Disease , 1995, Neurology.

[29]  B. Penke,et al.  Conformational mapping of amyloid peptides from the putative neurotoxic 25-35 region. , 1994, Biochemical and Biophysical Research Communications - BBRC.

[30]  Elizabeth A. Craig,et al.  Heat shock proteins and molecular chaperones: Mediators of protein conformation and turnover in the cell , 1994, Cell.

[31]  W. H. Gispen,et al.  Cerebral function in diabetes mellitus , 1994, Diabetologia.

[32]  A. Wallin,et al.  Comorbidity of other chronic age-dependent diseases in dementia , 1994, Aging.

[33]  Bruce A. Yankner,et al.  Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus , 1994, Nature.

[34]  Kenneth H. Johnson,et al.  Islet Amyloid Polypeptide in Human Insulinomas: Evidence for Intracellular Amyloidogenesis , 1994, Diabetes.

[35]  K. Mortel,et al.  Analysis of Familial and Individual Risk Factors Among Patients with Ischemic Vascular Dementia and Alzheimer's Disease , 1993, Angiology.

[36]  R. Mayeux,et al.  Clinical determinants of dememtia related to stroke , 1993, Annals of neurology.

[37]  K. Blennow,et al.  Low blood pressure and blood glucose levels in Alzheimer's disease Evidence for a hypometabolic disorder? , 1993, Journal of internal medicine.

[38]  Y. Stern,et al.  Risk factors for cerebrovascular disease as correlates of cognitive function in a stroke-free cohort. , 1993, Archives of neurology.

[39]  H. Braak,et al.  The human entorhinal cortex: normal morphology and lamina-specific pathology in various diseases , 1992, Neuroscience Research.

[40]  A. McCall.  The Impact of Diabetes on the CNS , 1992, Diabetes.

[41]  N. Holbrook,et al.  Stress-induced heat shock protein 70 expression in adrenal cortex: an adrenocorticotropic hormone-sensitive, age-dependent response. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[42]  D J Ballard,et al.  Clinical risk factors for Alzheimer's disease , 1991, Neurology.

[43]  I. J. Deary,et al.  Cumulative cognitive impairment following recurrent severe hypoglycaemia in adult patients with insulin-treated diabetes mellitus , 1991, Diabetologia.

[44]  J. Reed,et al.  Aggregation and secondary structure of synthetic amyloid βA4 peptides of Alzheimer's disease , 1991 .

[45]  E. Tangalos,et al.  Mayo Clinic Alzheimer’s Disease Patient Registry , 1990, Aging.

[46]  Anthony F Jorm,et al.  A case‐control study of Alzheimer's disease in Australia , 1990, Neurology.

[47]  I. Rainero,et al.  Genetic linkage studies suggest that Alzheimer's disease is not a single homogeneous disorder , 1990, Nature.

[48]  C. Betsholtz,et al.  Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[49]  Kenneth H. Johnson,et al.  Sequence divergence in a specific region of islet amyloid polypeptide (IAPP) explains differences in islet amyloid formation between species , 1989, FEBS letters.

[50]  R. Holman,et al.  Islet amyloid, increased A-cells, reduced B-cells and exocrine fibrosis: quantitative changes in the pancreas in type 2 diabetes. , 1988, Diabetes research.

[51]  L. G. Davis,et al.  Immunocytochemical localization of the precursor protein for β-amyloid in the rat central nervous system , 1988, Neuron.

[52]  G. Glenner,et al.  Amyloid fibrils formed from a segment of the pancreatic islet amyloid protein. , 1988, Biochemical and biophysical research communications.

[53]  G. Multhaup,et al.  Alzheimer's disease amyloidogenic glycoprotein: expression pattern in rat brain suggests a role in cell contact. , 1988, The EMBO journal.

[54]  G. Wolf-Klein,et al.  Are Alzheimer Patients Healthier? , 1988, Journal of the American Geriatrics Society.

[55]  M. Goedert.  Neuronal localization of amyloid beta protein precursor mRNA in normal human brain and in Alzheimer's disease. , 1987, The EMBO journal.

[56]  R. Turner,et al.  Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[57]  M. King,et al.  Concordance for Type 2 (non-insulin-dependent) diabetes mellitus in male twins , 1987, Diabetologia.

[58]  J. Haines,et al.  The genetic defect in familial Alzheimer's disease is not tightly linked to the amyloid β-protein gene , 1987, Nature.

[59]  C. Broeckhoven,et al.  Failure of familial Alzheimer's disease to segregate with the A4-amyloid gene in several European families , 1987, Nature.

[60]  J. Morrison,et al.  Localization of amyloid beta protein messenger RNA in brains from patients with Alzheimer's disease. , 1987, Science.

[61]  D. W. Hayden,et al.  Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islet cells. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[62]  K. Anderson,et al.  Epidemiology of diabetes mellitus in the elderly. The Framingham Study. , 1986, The American journal of medicine.

[63]  R. Martins,et al.  Neuronal origin of a cerebral amyloid: neurofibrillary tangles of Alzheimer's disease contain the same protein as the amyloid of plaque cores and blood vessels. , 1985, The EMBO journal.

[64]  C. Masters,et al.  Amyloid plaque core protein in Alzheimer disease and Down syndrome. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[65]  G. Glenner,et al.  Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein , 1984 .

[66]  W E Wilkinson,et al.  Alzheimer's disease: A study of epidemiological aspects , 1984, Annals of neurology.

[67]  D. Pyke,et al.  Diabetes in identical twins , 1981, Diabetologia.

[68]  E. Wilander,et al.  The influence of amyloid deposits on the islet volume in maturity onset diabetes mellitus , 1978, Diabetologia.

[69]  P. Schwartz.  SENILE CEREBRAL, PANCREATIC INSULAR AND CARDIAC AMYLOIDOSIS. , 1965, Transactions of the New York Academy of Sciences.

[70]  M. Dragunow,et al.  Increased expression and activation of c-Jun contributes to human amylin-induced apoptosis in pancreatic islet beta-cells. , 2002, Journal of molecular biology.

[71]  R. Sacco,et al.  Hypertension and diabetes mellitus as determinants of multiple lacunar infarcts. , 1995, Stroke.

[72]  N. Eberhardt,et al.  Islet Amyloid Polypeptide (IAPP) and Insulin Secretion , 1994 .

[73]  D. Leroith,et al.  Molecular Biology of Diabetes , 1994, Humana Press.

[74]  M. Franceschi,et al.  Clinical and epidemiological aspects of Alzheimer's disease with presenile onset: a case control study. , 1991, Neuroepidemiology.

[75]  D. W. Hayden,et al.  Immunolocalization of islet amyloid polypeptide (IAPP) in pancreatic beta cells by means of peroxidase-antiperoxidase (PAP) and protein A-gold techniques. , 1988, The American journal of pathology.

[76]  G. Glenner,et al.  Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. , 1984, Biochemical and biophysical research communications.